ACE and ovarian carcinoma: When analyses were restricted to women > 50 years old at diagnosis, inverse association between ACE inhibitor use and ovarian cancer mortality remained, whereas the risk estimates for associations between BBs or CCBs use and ovarian cancer mortality were attenuated (Supplementary Table 2, Additional file 1).